Search
Cardiolipin Biosynthesis CL(15:0/15:0/a-15:0/a-15:0)
smpdb.ca/view/SMP0204501MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(15:0/15:0/a-15:0/i-15:0)
smpdb.ca/view/SMP0204505MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
Cardiolipin Biosynthesis CL(15:0/15:0/i-15:0/i-15:0)
smpdb.ca/view/SMP0204557MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...
rPSGL-Ig
go.drugbank.com/drugs/DB06256InvestigationalRecombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.
Synonyms: rPSGL-Ig, rPSGL-1-IgMilatuzumab
go.drugbank.com/drugs/DB12943InvestigationalMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalIt has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies … Givinostat is a small molecule histone deacetylase (HDAC) inhibitor.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexAliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigationalAliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacio...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates